Mouse cardiac muscle cell line, HL-1

Details Mouse cardiac muscle cell line, HL-1 Mouse cardiac muscle cell line, HL-1

1999-04-22

2001-11-13

Duffy, Patricia A. (Department: 1645)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving antigen-antibody binding, specific binding protein...

C435S374000, C435S375000, C435S383000, C435S362000, C435S007100

Reexamination Certificate

active

06316207

ABSTRACT:

TECHNICAL FIELD
The present invention relates to a novel cell line (“HL-1”) derived from a transplantable mouse cardiomyocyte lineage (AT-1) wherein the cell line has the following characteristics: a) can be serially passaged greater than two hundred times and retain the ability to spontaneously contract: b) can be frozen, stored in, and recovered from liquid nitrogen, and revived upon thawing; c) can be cultured in serum-free medium; d) retains ultrastructural characteristics of in vitro adult atrial cardiac muscle cells; e) displays a pattern of gene expression similar to that of adult atrial myocytes including ANF, atrial natriuretic factor, &agr;-cardiac myosin heavy chain, &agr;-cardiac actin and connexin43; f) responds positively to immunohistochemical stains for desmin, sarcomeric myosin, and atrial natriuretic peptide; g) will give rise to tumors when injected subcutaneously into syngeneic mice; h) can secrete into the culture medium growth factors including basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), platelet derived growth factor (PGDF), epithelial growth factor (EGF), transforming growth factor beta 1(TGF-&bgr;1), and adrenomedullin; i) displays a cardiac-like, rapidly activating and inactivating delayed rectifier potassium current with biophysical and pharmacological characteristics that are nearly identical to those described for cardiac I
Kr
; j) displays time- and voltage-dependent inward currents that are most likely sodium and L-type calcium currents.
The present invention further relates to a cell culture system which can be used as an in vitro model of the cardiac muscle cell to screen and test cardiac drugs. This invention relates generally to a novel cell line, and specifically to a novel mouse cardiac muscle line, as well as to the use of these cells to produce and isolate factors in cardiac cells and/or screen cardiac drugs.
BACKGROUND OF THE INVENTION
Attempts to create a cardiac muscle cell line which actively proliferates in culture while maintaining the differentiated phenotype have to date not been successful. Transgenic mouse lines have been derived in which the simian virus SV40 large T antigen expression has been targeted to atrial and ventricular cardiomyocytes of the heart [Field, Science 239:10029-10033 (1988); Katz, et al. Am J. Physiol 262:H1867-H1876 (1992)]. Expression of this oncogene under control of the atrial natriuretic factor (ANF) promoter results in atrial hyperplasia whereas expression of this oncogene under control of the &agr;-cardiac myosin heavy chain promoter results in hyperplastic growth of both atrial and ventricles. AT-1 cells are atrial cardiomyocytes that were derived from the ANF-SV40 large T antigen construct [Delcarpio, et al. Circ. Res. 69:1591-1600 (1991)]. These highly differential myocytes have been maintained for over 6 years by serial passage as ectopic grafts in syngeneic mice. AT-1 cells can be easily cultured and maintain their cardiac phenotype; however, they can not be passaged in culture and must be maintained as a subcutaneous tumor lineage in syngeneic mice. On the other hand, a cardiac muscle cells line named AT-2 cells has been derived from atrial tissue of transgenic mice expressing SV40 large T antigen under control of the &agr;-cardiac myosin heavy chain promoter. At-2 cells rapidly divide in culture (average population doubling time of 24 hours) and can be easily passaged, but they totally lose their phenotype after about the tenth passage in culture [Katz, et al. Am J. Physiol. 262:H1867-H1876 (1992); Borisov and Claycomb, Annals of N.Y. Acad. Sci., 752:80-91 (1995)]. Attempts by others to produce a cardiac myocyte cell line have resulted in a similiar pattern of loss of phenotype. One of the first reports of a cardiac myocyte cell line was on the isolation of a clonal cell line from rat heart [Kimes and Brandt, Exp. Cell Res 98:367-381 (1976)]. These cells fused to form typical skeletal myotubes and they expressed skeletal muscle-specific creatine phosphokinase. Contamination of these cardiomyocyte cell line cultures with skeletal myoblasts was not, however, rigorously excluded. v-myc transformed quail cardiac myoblasts have been passaged over 60 times [Jaffredo, et al. Exp. Cell Res. 192:481-491 (1991)]. This line originates from myocardial tumors induced in 3 day-old quail embryos by microinjection of MC29 avian retrovirus carrying the myc-oncogene. These cells progressively lose their muscle markers with time in culture although co-culture of these cells with 3T3 mouse fibroblasts induces a moderate re-expression of muscle myosin. However, the localization of this protein is diffuse, and the cells did not form an organized contractile cytoskeleton and never exhibited contractile activity. Similar results on the establishment of a cell line from precardiac splanchnic mesoderm of a Japanese quail embryo was recently reported [Eisenberg, Anat. Rec. 232:30A (1992)]. During the establishment of this cell line muscle-specific markers were also lost. They could be induced to express desmin, sarcomeric myosin heavy chain and muscle actin by altering the culture conditions. Neither myofibrils nor contractile activity was detected in these cultured cells. Recently it was reported that human fetal cardiac muscle cells transfected with SV 40 T antigen could be maintained for over a year in culture. [Wang, et al. In Vitro Cell. Dev. Biol. 27:63-74 (1991) ]. These cells expressed several markets of early fetal human cardiac myocytes but did not retain contractile activity. Embryonic rat cardiac myocytes transfected with the v-myc and v-H-ras oncogenes have been reported to undergo multiple passages in culture and to retain the expression of several cardiac-specific genes [Engelmann, et. al. J. Mol. Cell. Cardiol. 25:197-213 (1993)]. In summary, to date no cardiac muscle cell line has been reported or is available that: 1) retains a highly differentiated adult cardiac myocyte phenotype; 2) maintains contractile activity; and 3) can be serially passaged in culture.
OBJECTS OF THE PRESENT INVENTION
It is the object of the present invention to provide a novel cardiac muscle cell line. It is a further object of the present invention to produce a novel cell culture system which can be used as an in vitro model of cardiac muscle to screen and to test cardiac drugs. It is a further object of this invention to use this novel mouse cardiac muscle line to produce and, to isolate factors in and from cardiac cells, and/or to screen cardiac drugs.


REFERENCES:
patent: WO 92/22636 (1992-12-01), None
patent: WO 98/18906 (1998-05-01), None
Daud et al. Am J Physiol 264 (65, pt. 2) H1693-H1700, 1993.*
Katz et al. Am J Physiol 262 (6, Pt. 2) H 1867-H 1876, 1992.*
Lanson et al. Cirulation 85 (5):1835-41, 1992.*
Cook et al. Am J Physiol 268 (4, Pt. 2) H1471-H1482, 1995.*
Folkman, J., Shing, Y., “Minireview: Angiogenesis”,The Journal of Biological Chemistry, vol. 267, No. 16., pp. 10931-10934, (Jun. 5, 1992).
Claycomb, W.C., Bradshaw, H.D., Jr., “Aquisition of Multiple Nuclei and the Activity of DNA Polymerase &agr; and Reinitiation of DNA Replication in Terminally Differentiated Adult Cardiac Muscle Cells in Culture”,Developmental Biology 99, pp. 331-337, (1983).
Claycomb, W.C., “Control of Cardiac Muscle Cell Division”,TCM, vol. 2, No. 6, pp. 231-236, (1992).
Claycomb, W.C., Moses, R.L., “Growth Factors and TPA Stimulate DNA Synthesis and Alter Morphology of Cultured Terminally Differentiated Adult Rat Cardiac Muscle Cells”,Developmental Biology127, pp. 257-265. (1988).
Chadwick, C.C., et al., “Identification of a Specific Radioligand for the Cardiac Rapidly Activating Delayed Rectifier K30Channel”,Circulation Research, vol. 72, No. 3, (Mar., 1993).
Koh, G.Y., Soonpaa, M.H., Klug, M.G., Filed, L.J., “Long-term Survival of AT-1 Cardiomyocyte Grafts in Syngeneic Myocardium”,Am. J. Physiolog.264, pp. H1727-H1733. (1993).
Delcarpio, J.B., Lanson, N.A., Jr., Field, L.J., Claycomb, W.C., Morphological Characterizat

Affiliated with

Also associated with

Rating

Mouse cardiac muscle cell line, HL-1 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Mouse cardiac muscle cell line, HL-1, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mouse cardiac muscle cell line, HL-1 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2617278